Product Images Tadalafil

The text shows a graph depicting the mean change from baseline in meters for placebo and tadalafil 40 mg. The x-axis shows the meters, and the y-axis depicts the number of subjects. The graph indicates that tadalafil 40 mg had a statistically significant improvement compared to placebo.*

This text appears to be a table with data related to a clinical study on the treatment of pulmonary arterial hypertension (PAH) using the drug tadalafil. The table indicates different study parameters such as the number of subjects, their demographics (age and gender), PAH etiology, baseline 6-minute walk distance, and baseline WHO functional class. The table also includes the change in 6-minute walk distance for subjects treated with tadalafil compared to placebo, along with 95% confidence intervals. The usefulness of the data depends on the context and purpose for which it is being evaluated.*

This appears to be a graph comparing the percentage of patients without clinical worsening over time between a group taking tadalafil (at 20mg and 40mg doses) and a placebo group. The x-axis is labeled as "Time to Clinical Worsening in Days" and the y-axis appears to show the percentage of patients without clinical worsening, with values ranging from 0% to 100%.*

This appears to be an output of a medication packaging or label. The text includes information such as the name of the medication (Tadalafil), dosage instructions, manufacturer (Torrent Pharmaceuticals), and a product code (NOC 13668-581-30). However, the text is not fully readable and contains errors, making it difficult to interpret the full meaning and context.*

This text appears to be a chart showing the effects of various drugs on the absorption of Tadalafil. It includes information such as the drug administered, whether it is a CYP3A inhibitor or inducer, and how it affects the AUC and Emax of Tadalafil. The chart also includes conclusions and recommendations regarding dose adjustment and whether to avoid certain drugs.*